605
Views
8
CrossRef citations to date
0
Altmetric
Review Article

Rheumatic diseases associated with immune checkpoint inhibitors in cancer immunotherapy

, , &
Pages 721-732 | Received 19 Jul 2018, Accepted 01 Oct 2018, Published online: 20 Dec 2018
 

Abstract

Immune checkpoint inhibitors (ICIs) have drastically altered cancer treatment paradigms, with increasing numbers of novel ICIs being currently evaluated in numerous clinical trials for various cancers. ICIs release ‘brakes’ against tumor immunity to control cancer growth through T cell-dependent anti-tumor activity. Meanwhile, side effects associated with ICIs are directly related to their mechanism of action, as nonspecific immune activation targeting non-tumor organs results in undesirable off-target inflammation and autoimmunity. Accumulating data reveal that immune-related adverse events (irAEs) of ICIs in cancer patients can resemble various rheumatic diseases. Moreover, while patients with preexisting rheumatic diseases can theoretically experience irAEs and disease flares, observational studies have shown that ICIs can be used successfully in these patients. As ICIs continue to provide long-lasting disease control in cancer patients and their usage correspondingly increases, the rheumatologist will be managing new ICI-associated clinical entities mimicking common autoimmune diseases and will need to be prepared to rapidly diagnose and treat these irAEs. Early recognition and treatment of these rheumatic adverse events will allow for improved outcomes and quality of life for cancer patients faced with previously rapidly fatal disease.

Conflict of interest

None.

Additional information

Funding

This study was supported in part by a grant of the Ministry of Health, Labour, and Welfare, Japan [Grant Number 150401-01 (C.M.) and 180101-01 (C.M.)], JSPS KAKENHI Grant Numbers JP16H05345 (C.M.), JP18H02782 (K.O.), and JP17K10008 (R.H.).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.